Sheryl L. Szeinbach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sheryl L. Szeinbach has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Andrew Beyer
3 shared publicationsEnrique Seoane‐Vazquez
International Center for Pharmaceutical Economics and Policy Massachusetts College of Pharmacy and Health Sciences Boston MA USA
3 shared publications- Rosa Rodriguez-Monguio
University of Massachusetts Amherst-School of Public Health and Health Sciences, Amherst, MA
3 shared publications B. P. Yawn
Department of Research Olmsted Medical Center Rochester MN USA
2 shared publicationsD. Littlefield
Department of Research Olmsted Medical Center Rochester MN USA
2 shared publicationsEnrique C Seoane-Vazquez
2 shared publications
Latest Publications
- 6 November 2014
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 21 (1) , 153-159
Evaluating catheter complications and outcomes in patients receiving home parenteral nutrition
Rationale, aims and objectives: We describe catheter complications and outcomes in patients who received home parenteral nutrition (HPN) therapy.Methods: Retrospective chart data were obtained from Boston Home Infusion agency that provided HPN therapy to 212 patients [International Classification of Diseases, 9th revision (ICD‐9) codes: gastrointestinal (GI)‐related disorders and oncology] between 1 January 2005 and 30 September 2011.Results: Of the 163 patients who represented 19 104 home‐catheter days, 19 (11.7%) patients experienced 25 catheter complications (CCs; 12 occlusions, 11 central line‐associated bloodstream infections, one thrombosis and one line dislodgment). The overall CC rate was 1.30 per 1000 peripherally inserted central catheter (PICC)‐line days. The mean number of PICC‐line days (278.7 ± 335.0 vs. 95.9 ± 154.0) and patients with at least one hospital admission were significantly higher for patients with one or more CCs compared with patients with no CCs (P < 0.03).Conclusion: Patients who experienced CCs had more PICC‐line days, more hospital admissions and had an ICD‐9 code for GI‐related disorders compared with patients with oncology‐related diagnoses.
- 6 November 2014
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 21 (1) , 153-159
Evaluating catheter complications and outcomes in patients receiving home parenteral nutrition
Rationale, aims and objectives: We describe catheter complications and outcomes in patients who received home parenteral nutrition (HPN) therapy.Methods: Retrospective chart data were obtained from Boston Home Infusion agency that provided HPN therapy to 212 patients [International Classification of Diseases, 9th revision (ICD‐9) codes: gastrointestinal (GI)‐related disorders and oncology] between 1 January 2005 and 30 September 2011.Results: Of the 163 patients who represented 19 104 home‐catheter days, 19 (11.7%) patients experienced 25 catheter complications (CCs; 12 occlusions, 11 central line‐associated bloodstream infections, one thrombosis and one line dislodgment). The overall CC rate was 1.30 per 1000 peripherally inserted central catheter (PICC)‐line days. The mean number of PICC‐line days (278.7 ± 335.0 vs. 95.9 ± 154.0) and patients with at least one hospital admission were significantly higher for patients with one or more CCs compared with patients with no CCs (P < 0.03).Conclusion: Patients who experienced CCs had more PICC‐line days, more hospital admissions and had an ICD‐9 code for GI‐related disorders compared with patients with oncology‐related diagnoses.
- 5 March 2013
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (7) , 750-751
Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument – authors’ reply
- 5 March 2013
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (7) , 750-751
Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument – authors’ reply
- 7 January 2013
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (5) , 573-582
Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument
Summary: Background: While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is oftentimes attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. treatment satisfaction) has not been developed.Aim: To describe the development and validation the chronic Hepatitis C Virus Treatment Satisfaction (HCVTSat) instrument.Methods: Focus groups, expert review and cognitive debriefing were used to develop a draft 37‐item instrument (scale: 1 = not important at all; 5 = extremely important). The preliminary instrument was administered to a pre‐test sample of 145 patients through Mayo Clinic, Rochester, MN. A refined HCVTSat was administered to a main sample of 333 participants with a chronic HCV diagnosis through Harris Interactive.Results: The HCVTSat was completed by 333 participants with an average age of 51 (s.d. = 12.1) years, 55% male, current or previous HCV treatment experience, and a diagnosis of HCV for approximately 12 (s.d. = 8.9) years. Twelve items for the 3 dimensions, Treatment Experience (TE), Side Effects (SE) and Social Aspects (SA), were internally consistent (Cronbach's α range: 0.70–0.90), responsive and valid. Confirmatory factor analysis (goodness‐of‐fit indexes: χ2 = 20.9, df = 23, P = 0.59; CFI = 1.00, GFI = 0.99, TFI = 1.00, RMSEA = 0.001) revealed a better fit with 9 items. All path coefficients were significant (P < 0.05). SE and SA were strong predictors of TE, while TE was positively associated with the 1‐item global measure of TS (path coefficient = 0.12).Conclusions: The 10‐item HCVTSat demonstrated valid psychometric properties and assessed patient satisfaction with HCV therapies. However, additional studies are needed to validate the HCVTSat in conjunction with SVR and in patients in underrepresented populations.
- 7 January 2013
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 37 (5) , 573-582
Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument
Summary: Background: While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is oftentimes attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. treatment satisfaction) has not been developed.Aim: To describe the development and validation the chronic Hepatitis C Virus Treatment Satisfaction (HCVTSat) instrument.Methods: Focus groups, expert review and cognitive debriefing were used to develop a draft 37‐item instrument (scale: 1 = not important at all; 5 = extremely important). The preliminary instrument was administered to a pre‐test sample of 145 patients through Mayo Clinic, Rochester, MN. A refined HCVTSat was administered to a main sample of 333 participants with a chronic HCV diagnosis through Harris Interactive.Results: The HCVTSat was completed by 333 participants with an average age of 51 (s.d. = 12.1) years, 55% male, current or previous HCV treatment experience, and a diagnosis of HCV for approximately 12 (s.d. = 8.9) years. Twelve items for the 3 dimensions, Treatment Experience (TE), Side Effects (SE) and Social Aspects (SA), were internally consistent (Cronbach's α range: 0.70–0.90), responsive and valid. Confirmatory factor analysis (goodness‐of‐fit indexes: χ2 = 20.9, df = 23, P = 0.59; CFI = 1.00, GFI = 0.99, TFI = 1.00, RMSEA = 0.001) revealed a better fit with 9 items. All path coefficients were significant (P < 0.05). SE and SA were strong predictors of TE, while TE was positively associated with the 1‐item global measure of TS (path coefficient = 0.12).Conclusions: The 10‐item HCVTSat demonstrated valid psychometric properties and assessed patient satisfaction with HCV therapies. However, additional studies are needed to validate the HCVTSat in conjunction with SVR and in patients in underrepresented populations.
- Open Access
- 1 August 2012
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 6, 631-41
Development of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument
Peer reviewed article authored by (Szeinbach SL, Seoane-Vazquez E, Summers KH). Read article or submit your manuscript for publishing.
- 1 August 2012
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 6, 631-41
Open AccessDevelopment of a men's Preference for Testosterone Replacement Therapy (P-TRT) instrument
Peer reviewed article authored by (Szeinbach SL, Seoane-Vazquez E, Summers KH). Read article or submit your manuscript for publishing.
- 14 May 2011
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (7) , 772-777
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
Purpose: Economic factors, market dynamics, and safety issues are largely responsible for decisions to withdraw pharmaceutical products from the market. In this study, new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) were examined in the USA from 1980 to 2009.Methods: Data were obtained from the FDA, Micromedex, Medline, and Lexis‐Nexis. Descriptive analyses were used to classify product discontinuations by therapeutic category, time frame for discontinuation, and reason for withdrawal.Results: There were 740 NMEs approved by the FDA during the study period. As of 1 December 2010, the number of drugs discontinued was 118 (15.9%). Discontinuations were the highest for antiparasitic products, insecticides, and repellents (6, 33.3% of approvals), systemic hormonal preparations excluding sex hormones and insulins (5, 33.3%), musculo‐skeletal system (11, 32.4%), diagnostic agents (16, 28.1%), and anti‐infectives for systemic use (27, 25.2%). Safety was the primary reason for withdrawing 26 drugs (3.5% of approvals).Conclusions: Approximately one in seven approved NMEs were discontinued from the market in the period of 1980–2009. Less than one‐quarter (22%) of the total withdrawals were attributed to safety reasons. An ongoing evaluation of new drugs throughout their product life cycle is important to determine their efficacy, safety, and value to society. Copyright © 2011 John Wiley & Sons, Ltd.
- 14 May 2011
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (7) , 772-777
Market withdrawal of new molecular entities approved in the United States from 1980 to 2009
Purpose: Economic factors, market dynamics, and safety issues are largely responsible for decisions to withdraw pharmaceutical products from the market. In this study, new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) were examined in the USA from 1980 to 2009.Methods: Data were obtained from the FDA, Micromedex, Medline, and Lexis‐Nexis. Descriptive analyses were used to classify product discontinuations by therapeutic category, time frame for discontinuation, and reason for withdrawal.Results: There were 740 NMEs approved by the FDA during the study period. As of 1 December 2010, the number of drugs discontinued was 118 (15.9%). Discontinuations were the highest for antiparasitic products, insecticides, and repellents (6, 33.3% of approvals), systemic hormonal preparations excluding sex hormones and insulins (5, 33.3%), musculo‐skeletal system (11, 32.4%), diagnostic agents (16, 28.1%), and anti‐infectives for systemic use (27, 25.2%). Safety was the primary reason for withdrawing 26 drugs (3.5% of approvals).Conclusions: Approximately one in seven approved NMEs were discontinued from the market in the period of 1980–2009. Less than one‐quarter (22%) of the total withdrawals were attributed to safety reasons. An ongoing evaluation of new drugs throughout their product life cycle is important to determine their efficacy, safety, and value to society. Copyright © 2011 John Wiley & Sons, Ltd.
- 12 February 2010
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 16 (1) , 192-195
Managing oral anticoagulation therapy by pharmacists in a specialty heart hospital
- 12 February 2010
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 16 (1) , 192-195
Managing oral anticoagulation therapy by pharmacists in a specialty heart hospital
- 1 September 2009
- Published by Elsevier in Value in Health
- Vol. 12 (6) , 1004-1010
Psychometric Development and Validation of the Chronic Constipation Treatment Satisfaction Questionnaire (CTSAT-Q)
- 1 September 2009
- Published by Elsevier in Value in Health
- Vol. 12 (6) , 1004-1010
Psychometric Development and Validation of the Chronic Constipation Treatment Satisfaction Questionnaire (CTSAT-Q)
- 1 January 2009
- Vol. 64 (1) , 171-81
Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
The Uruguay Round Agreements Act (URAA) was enacted by the United States Congress in 1994. The URAA provided substantial modifications to the framework for U.S. patent law that came into effect January 1, 1953. Changes in patent regulation are especially important in the pharmaceutical sector because the patent system determines, in large part, the reward that an inventor can derive from discovery of a new drug. Most pharmaceutical patents are classified as utility patents. Pharmaceutical patents may include claims for the active ingredient per se, for the formulation of the active ingredient for use as a pharmaceutical, for therapeutic indications and uses, and for methods of manufacturing the drug. The U.S. has a First-to-Invent system to establishing the right of priority of an invention, but most countries have a First-to-File priority system. The First-to-Invent system allows for public disclosure of inventions prior to patent filing. In contrast, the First-to-File system encourages early filing of patent applications. In both systems, filing an application for a patent as soon as the drug is discovered allows inventors to obtain an earlier date of invention relative to potential competitors and establish the right of priority over the invention.
- 1 January 2009
- Vol. 64 (1) , 171-81
Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
The Uruguay Round Agreements Act (URAA) was enacted by the United States Congress in 1994. The URAA provided substantial modifications to the framework for U.S. patent law that came into effect January 1, 1953. Changes in patent regulation are especially important in the pharmaceutical sector because the patent system determines, in large part, the reward that an inventor can derive from discovery of a new drug. Most pharmaceutical patents are classified as utility patents. Pharmaceutical patents may include claims for the active ingredient per se, for the formulation of the active ingredient for use as a pharmaceutical, for therapeutic indications and uses, and for methods of manufacturing the drug. The U.S. has a First-to-Invent system to establishing the right of priority of an invention, but most countries have a First-to-File priority system. The First-to-Invent system allows for public disclosure of inventions prior to patent filing. In contrast, the First-to-File system encourages early filing of patent applications. In both systems, filing an application for a patent as soon as the drug is discovered allows inventors to obtain an earlier date of invention relative to potential competitors and establish the right of priority over the invention.
- Open Access
- 16 December 2008
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 3 (1) , 33
Incentives for orphan drug research and development in the United States
The Orphan Drug Act (1983) established several incentives to encourage the development of orphan drugs (ODs) to treat rare diseases and conditions. This study analyzed the characteristics of OD designations, approvals, sponsors, and evaluated the effective patent and market exclusivity life of orphan new molecular entities (NMEs) approved in the US between 1983 and 2007.
- 16 December 2008
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 3 (1) , 33
Open AccessIncentives for orphan drug research and development in the United States
The Orphan Drug Act (1983) established several incentives to encourage the development of orphan drugs (ODs) to treat rare diseases and conditions. This study analyzed the characteristics of OD designations, approvals, sponsors, and evaluated the effective patent and market exclusivity life of orphan new molecular entities (NMEs) approved in the US between 1983 and 2007.
- Open Access
- 26 August 2008
- Published by Springer Nature in BMC Family Practice
- Vol. 9 (1) , 47
Testing for allergic disease: Parameters considered and test value
Test results for allergic disease are especially valuable to allergists and family physicians for clinical evaluation, decisions to treat, and to determine needs for referral.
- 26 August 2008
- Published by Springer Nature in BMC Family Practice
- Vol. 9 (1) , 47
Open AccessTesting for allergic disease: Parameters considered and test value
Test results for allergic disease are especially valuable to allergists and family physicians for clinical evaluation, decisions to treat, and to determine needs for referral.